Quibim adds industry-leading cancer detection capability to prostate AI product

QP-Prostate was trained on pathology data and has been CE and UKCA marked

 
18 January 2024, New York / Valencia / CambridgeQuibim, the company pioneering the use of imaging biomarkers for precision medicine, can reveal it has added an industry-leading cancer detection capability to its prostate tool based on AI, QP-Prostate. The updated product, which uses algorithms trained on actual pathology data as ground truth, has been given a CE mark for the European Union and a UKCA mark for the United Kingdom, meaning it is cleared to be used by clinicians in those markets.

As MRI scans have become standard-of-care for prostate cancer, and populations at higher risk of the disease continue to grow, many radiology departments have not had the proper resources in place to handle the avalanche of advanced medical imagery needing to be analysed to appropriately manage prostate cancer patients. QP-Prostate, one of Quibim’s flagship products, was developed to overcome this challenge by using AI to speed up the processing of images, increase the accuracy of radiologists who identify signs of cancer and help them pass on actionable data points to oncology departments.

QP-Prostate stands out in the market as it speeds up processes without compromising on quality, with a validated international study showing that the software efficiently segments imagery of the prostate gland with 88% accuracy1. The algorithm also segments key subregions and zones and calculates prostate volume, aiding in prostate-specific antigen density calculations and fusion biopsy planning.

From this year, QP-Prostate can also be used by EU and UK clinicians for AI-driven lesion detection thanks to algorithms trained with post-biopsy pathology data as ground truth, rather than radiology assessments. This is an industry-first and will help radiologists enhance diagnostic accuracy in terms of high specificity beyond high sensitivity as well as shortened reporting times.

Dr Angel Alberich Bayarri, Quibim’s founder and CEO, commented: “It is fantastic, after so much hard work, to finally be at a stage when our lesion detection capability for prostate can be rolled out across the EU and the UK. At Quibim we are acutely aware of the real-life impact our products are having, which is why we’re always striving to expand and enhance our products in line with scientific and health industry advancements. We look forward to working with radiologists to help them further improve the early-stage care for patients with suspected or confirmed prostate cancer, which is a group that is sadly growing at a rapid pace in many countries.”

David Bazaga, Product Manager for QP-Prostate, commented: “The importance of enhancing lesion detection in medical imaging analysis has been apparent for a while, and it has been great to work with our own technical experts and partners in the healthcare sector to ensure Quibim’s product is fitted to their precise needs. Using pathology data to train and validate the algorithm has been critical and something we look forward to seeing the real-life results of in the near future.”

About Quibim

Quibim is a company designing pioneering tools that unlock imaging data to improve patient outcomes. With offices in New York (United States), Cambridge (UK), Valencia, Madrid, and Barcelona (Spain), the company was born from the ambition of turning imaging into a catalyst for precision health. Quibim leads the forefront of imaging biomarkers research in life sciences, pioneering the development of advanced algorithms that transform imaging data into actionable predictions in oncology, immunology and neurology. The company leverages the capabilities of MRI, CT, and PET imaging to create regulatory-cleared Medical Devices that are seamlessly integrated into the workflows of healthcare providers worldwide. More than 150+ sites are using Quibim products globally.

http://quibim.com/  

Contact information

quibim@theproffice.com

1. https://pubmed.ncbi.nlm.nih.gov/36690774/